| Revision as of 19:17, 20 September 2011 editBogBot (talk | contribs)Bots53,132 edits populated new fields in {{drugbox}} and reordered per bot approval. Report errors and suggestions to User_talk:BogBot← Previous edit |
Latest revision as of 23:50, 3 March 2024 edit undoSimLibrarian (talk | contribs)Extended confirmed users124,300 editsm →See also: make link directTag: Visual edit |
| (25 intermediate revisions by 22 users not shown) |
| Line 1: |
Line 1: |
|
|
{{Short description|Combination drug}} |
|
⚫ |
{{Use dmy dates|date=March 2020}} |
|
{{Drugbox |
|
{{Drugbox |
|
|
| Verifiedfields = changed |
| ⚫ |
| verifiedrevid = 432045804 |
|
|
|
| Watchedfields = changed |
|
⚫ |
| verifiedrevid = 451549798 |
|
|
|
|
|
<!--Combo data--> |
|
<!--Combo data--> |
| Line 10: |
Line 14: |
|
|
|
|
|
<!--Clinical data--> |
|
<!--Clinical data--> |
|
| tradename = |
|
| tradename = OsvaRen, Renepho |
|
| pregnancy_category = n/a |
|
| pregnancy_category = Not tested |
|
| legal_status = Rx Prescription only |
|
| legal_status = Rx |
|
| routes_of_administration = Oral |
|
| routes_of_administration = Oral |
|
|
| Drugs.com = {{Drugs.com|UK|osvaren-435-mg-235-mg-film-coated-tablets-spc-9688}} |
|
|
|
|
|
<!--Identifiers--> |
|
<!--Identifiers--> |
|
| CAS_number = 62-54-4 |
|
| CAS_number = 1173882-48-8 |
|
| CAS_supplemental = 546-93-0 |
|
|
| ATC_prefix = V03 |
|
| ATC_prefix = V03 |
|
| ATC_suffix = AE04 |
|
| ATC_suffix = AE04 |
|
| PubChem = 11029 |
|
|
|
|
|
|
<!--Chemical data--> |
|
<!--Chemical data--> |
|
}} |
|
}} |
|
|
|
|
|
'''Calcium acetate/magnesium carbonate''' is a fixed-dose combination drug that contains 110 mg ] and 60 mg ] indicated as a ] for dialysis patients suffering from ] (abnormal high serum phosphorus levels).<ref name=Osvaren>Osvaren – Summary of Product Characteristics; Retrieved on 17 January 2010.</ref> It is registered by ] under the trade names '''Renepho''' (Belgium) and '''OsvaRen''' (other ]). |
|
'''Calcium acetate/magnesium carbonate''' is a fixed-dose combination drug that contains 110 mg ] and 60 mg ] ions and is indicated as a ] for ] patients with ] (abnormal high serum phosphorus levels).<ref name=Osvaren>{{cite web | title = OsvaRen 435 mg / 235 mg film-coated tablets | url = http://www.freseniusmedicalcare.co.uk/wp-content/uploads/2013/09/PIL-OsvaRen.pdf | publisher = Fresenius Medical Care | location = Nottinghamshire, UK | date = February 2011 }}</ref> It is registered by ] under the trade names '''Renepho''' (Belgium) and '''OsvaRen''' (a number of other European countries). |
|
|
|
|
|
==Clinical use== |
|
==Clinical use== |
|
|
|
|
|
] is contained in food with high protein content as well as in processed food. It is absorbed by the gut. Healthy kidneys remove excess phosphorus from the body. One of the consequences of ] is inadequate removal of phosphorus resulting in increased serum phosphorus levels. This may worsen the overproduction of parathyroid hormone (]), may lead to calcification of blood vessels and is associated with cardiovascular mortality.<ref name=KDIGO>National Kidney Foundation, Kidney Disease Improving Global Outcomes (KDIGO). Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney International, Aug. 2009; 42: pp. 1–130.</ref> In addition to dialysis therapy and dietary restrictions, a pharmaceutical therapy to lower serum phosphorus levels is recommended.<ref>“What are medications for phosphorus control?”, National Kidney Foundation, URL: http://www.kidney.org/atoz/content/phosphorus.cfm ; Retrieved on 17 January 2010</ref> |
|
] is contained in food with high ] content as well as in ]. It is absorbed by the ].<ref>{{Cite web |url= http://lpi.oregonstate.edu/infocenter/minerals/phosphorus/ |title = Phosphorus|date = 23 April 2014}}</ref> Healthy ]s remove excess phosphorus from the body. One of the consequences of ] is inadequate removal of phosphorus resulting in increased ] phosphorus levels. This may worsen the overproduction of parathyroid hormone (]), and may lead to ], ] of ]s and is associated with ] mortality (the so-called ], CKD-MBD).<ref name="KDIGO">{{cite journal | vauthors = Moe SM, Drüeke TB, Block GA, Cannata-Andía JB, Elder GJ, Fukagawa M, Jorgetti V, Ketteler M, Langman CB, Levin A, MacLeod AM, McCann L, McCullough PA, Ott SM, Wang AY, Weisinger JR, Wheeler DC, Persson R, Earley A, Moorthi R, Uhlig K | display-authors = 6 | collaboration = Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group | title = KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) | journal = Kidney International. Supplement | volume = 76 | issue = 113 Suppl | pages = S1–S2 | date = August 2009 | pmid = 19644521 | doi = 10.1038/ki.2009.188 | doi-access = free }}</ref> In addition to dialysis therapy and dietary restrictions, a pharmaceutical therapy to lower serum phosphorus levels is recommended.<ref>{{cite web|title=What are medications for phosphorus control?|publisher=National Kidney Foundation |url= http://www.kidney.org/atoz/content/phosphorus.cfm |accessdate=17 January 2010}}</ref> |
|
|
|
|
|
==Mechanism of action== |
|
==Mechanism of action== |
|
|
|
|
|
Calcium acetate/magnesium carbonate is taken orally together with the meal.<ref name=Osvaren /> Calcium acetate and magnesium carbonate compounds bind phosphorus derived from food thereby forming indigestible phosphate salts in the intestine that are subsequently excreted with the faeces. The aim of the therapy is to reach a normal serum phosphorus level, i.e. between 0.81 - 1.45 mmol/l (2.5 - 4.5 mg/dl).<ref name=KDIGO /> |
|
Calcium acetate/magnesium carbonate is taken orally together with the meal.<ref name=Osvaren /> Calcium acetate and magnesium carbonate compounds bind phosphorus derived from food thereby forming indigestible phosphate salts in the intestine that are subsequently excreted with the faeces. The aim of the therapy is to reach a normal serum phosphorus level, i.e. between 0.81 and 1.45 mmol/L (2.5–4.5 mg/dL).<ref name=KDIGO /> |
|
|
|
|
|
==Side effects== |
|
==Side effects== |
| Line 40: |
Line 43: |
|
|
|
|
|
==See also== |
|
==See also== |
|
* ] |
|
|
* ] |
|
|
* ] |
|
|
* ] |
|
|
* ] |
|
|
* ] |
|
* ] |
|
|
* ] |
|
|
* ] |
|
|
|
|
|
==References== |
|
==References== |
| Line 51: |
Line 51: |
|
|
|
|
|
==External links== |
|
==External links== |
|
* - kidney.org |
|
* – National Kidney Foundation |
|
* - fmc-renalpharma.com |
|
* – fmc-renalpharma.com |
|
|
|
|
|
|
{{Drugs for treatment of hyperkalemia and hyperphosphatemia}} |
| ⚫ |
{{Use dmy dates|date=January 2011}} |
|
|
|
|
|
|
{{DEFAULTSORT:Calcium Acetate/Magnesium Carbonate}} |
|
{{DEFAULTSORT:Calcium Acetate Magnesium Carbonate}} |
|
] |
|
] |
|
] |
|
] |
|
|
|
|
] |
|